Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives

International Journal of Bipolar Disorders

Table 4 Metabolic syndrome and insulin resistance in patients with bipolar disorder

	Model	B	95% CI	P-value
1	Metabolic syndrome
a	Illness duration^a	0.637	0.409–0.993	0.047
b	BD type I vs. type II	0.769	0.345–1.705	0.5
c	Lithium	0.993	0.438–2.252	1.0
d	Antipsychotics	0.845	0.361–1.981	0.7
e	Antiepileptics	0.782	0.350–1.748	0.5
f	Antidepressants	2.517	1.717–3.691	0.7
g	Medication with metabolic adverse effects	2.325	0.873–6.194	0.1
2	Insulin resistance
a	Illness duration^a	0.987	0.974–1.000	0.056
b	BD type I vs. type II	0.891	0.745–1.065	0.2
c	Lithium	1.242	1.045–1.478	0.014
d	Antipsychotics	1.082	0.903–1.294	0.4
e	Antiepileptics	0.874	0.736–1.040	0.1
f	Antidepressants	1.075	0.882–1.310	0.3
g	Medication with metabolic adverse effects	1.298	1.088–1.550	0.004

Model 1: Separate generalized linear mixed models of metabolic syndrome (a–g) in patients with BD, adjusted for age and sex. B represents odds ratios
Model 2: Separate linear mixed models of insulin resistance (a–g) in patients with BD, adjusted for age and sex. B represents back transformed beta values
BD I and BD II: Bipolar Disorder type I and II, respectively. ^aIllness duration was defined as time from first episode (depressive, hypomanic, manic or mixed episode)